Online inquiry

IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4700MR)

This product GTTS-WQ4700MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4700MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4644MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ12496MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ9724MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ4109MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ152MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ14266MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ4128MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW